GlassScriptPhysician profile
Alma M Mas-Ramirez
NPI 1861742066
$9,471.39
in general payments reported to CMS, 2019-2025
26 companies · $827 in 2025
The $827 reported for 2025 was more than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,193 · 2020: $1,351 · 2021: $2,818 · 2022: $199 · 2023: $421 · 2024: $662 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,910.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $4,006.27 | 2019-2022 | |
| Alcon Vision LLC | $1,935.64 | 2019-2025 | Clareon, Tryptyr, Hydrus Microstent |
| Abbvie INC. | $794.50 | 2023-2025 | |
| Kala Pharmaceuticals, INC. | $383.99 | 2019-2021 | |
| Sight Sciences, INC. | $343.20 | 2019-2024 | Omni Surgical System |
| Mallinckrodt Hospital Products INC. | $276.03 | 2021-2023 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $247.54 | 2019 | |
| Novartis Pharmaceuticals Corporation | $204.12 | 2019-2023 | |
| Rxsight INC | $172.75 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal) |
| Tarsus Pharmaceuticals, INC. | $134.38 | 2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $130.10 | 2020-2021 | |
| Insmed, INC. | $122.83 | 2019 | |
| Sun Pharmaceutical Industries INC. | $104.00 | 2025 | |
| Harrow Eye, LLC | $102.52 | 2025 | Vevye |
| Ivantis, INC | $99.19 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $72.59 | 2019-2021 | |
| Horizon Therapeutics Plc | $59.27 | 2021-2023 | Tepezza |
| Ucb, INC. | $51.19 | 2023-2024 | Rystiggo |
| Ocular Therapeutix, INC. | $45.98 | 2021-2024 | Dextenza |
| New World Medical,INC. | $44.73 | 2024-2025 | Clearpath, Streamline, Kahook Dual Blade |
| Amgen INC. | $42.06 | 2024-2025 | Tepezza |
| Glaukos Corporation | $30.40 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $23.37 | 2023 | Xiidra |
| Dompe US, INC. | $18.32 | 2025 | Oxervate |
| Biotissue Holdings INC. | $13.57 | 2019 | |
| Oyster Point Pharma, INC. | $12.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alma Mas-Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.